A Phase IV, Open-Label, Single-Center, Prospective, Observational, 20-Year Follow-Up Study Assessing Long-Term Persistence Of Protective Antibody Levels Against The Hepatitis A virus (HAV) In Healthy Volunteers Vaccinated With 2 Doses Of Inactivated Hepatitis A Vaccine (Epaxal) between 1992 and 1995.

Trial Profile

A Phase IV, Open-Label, Single-Center, Prospective, Observational, 20-Year Follow-Up Study Assessing Long-Term Persistence Of Protective Antibody Levels Against The Hepatitis A virus (HAV) In Healthy Volunteers Vaccinated With 2 Doses Of Inactivated Hepatitis A Vaccine (Epaxal) between 1992 and 1995.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary)
  • Indications Hepatitis A
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 09 Feb 2017 Results published in the Vaccine Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top